Article
The collaboration between med fusion and GenomOncology promises improved outcomes in personalized cancer trials.
med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. The companies believe that GenomOnoclogy’s proprietary technology platform, the GO Clinical WorkbenchTM, and support services will complement med fusion’s expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
Press release: http://bit.ly/1tBLSsz